Effects of Liraglutide on GLP-1, GIP and glucagon concentrations in persons with type 2 diabetes with multiple daily insulin injections during a 24-week period

被引：0
|
作者：
Koci, M. [1 ]
Jansson, P. -A. [2 ]
Fatulla, P. [2 ]
Bergqvist, K. [3 ]
Ahmadi, S. Seyed [2 ]
Imberg, H. [2 ]
Hirsch, I. [4 ]
Mellander, O. [5 ]
Lind, M. [2 ]
机构：
[1] Sahlgrens Univ Hosp, Dept Endocrinol & Diabet, Gothenburg, Sweden
[2] Gothenburg Univ, Dept Mol & Clini cal Med, Gothenburg, Sweden
[3] Gothenburg Univ, Dept Infect Dis, Gothenburg, Sweden
[4] UW Med Diabet Inst, Div Metab Endocrinol & Nutr, Seattle, WA USA
[5] Lund Univ, Dept Clin Sci Malmo, Malmo, Sweden
来源：
DIABETOLOGIA | 2024年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
83
引用
收藏
页码：S47 / S47
页数：1
相关论文
共 50 条
  • [41] The DPPIV inhibitor, LAF237, reduces fasting and postprandial glucose in subjects with type 2 diabetes over a 4 week period by increasing active GLP-1, sustaining insulin and reducing glucagon
    Ahren, B
    Landin-Olsson, M
    Jansson, PA
    Eriksson, J
    Pacini, G
    Thomaseth, K
    Schweizer, A
    DIABETES, 2003, 52 : A15 - A15
  • [42] The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
    Frias, Juan Pablo
    Bastyr, Edward J., III
    Vignati, Louis
    Tschoep, Matthias H.
    Schmitt, Christophe
    Owen, Klara
    Christensen, Rune Haubo
    DiMarchi, Richard D.
    CELL METABOLISM, 2017, 26 (02) : 343 - +
  • [43] Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
    Hartman, Mark L.
    Sanyal, Arun J.
    Loomba, Rohit
    Wilson, Jonathan M.
    Nikooienejad, Amir
    Bray, Ross
    Karanikas, Chrisanthi A.
    Duffin, Kevin L.
    Robins, Deborah A.
    Haupt, Axel
    DIABETES CARE, 2020, 43 (06) : 1352 - 1355
  • [44] The gut hormone GLP-1 improves the postprandial (PP) glycaemia in type 2 diabetes mellitus by insulin, glucagon, and gastric emptying
    Aulinger, B.
    Bedorf, A.
    Kutscherauer, G.
    Goeke, B.
    Schirra, J.
    DIABETOLOGIA, 2012, 55 : S301 - S301
  • [45] Effect of the GLP-1 Receptor Agonist Lixisenatide on Glucagon Counterregulation to Hypoglycemia in Subjects with Insulin-Treated Type 2 Diabetes
    Ahren, Bo
    Farngren, Johan
    Persson, Margaretha
    DIABETES, 2015, 64 : A283 - A283
  • [46] Phase 2, randomised, placebo-controlled trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in subjects with overweight or obesity: a 24-week interim analysis
    Aronne, L.
    Harris, M. S.
    Roberts, M. S.
    Suschak, J.
    Tomah, S.
    He, L.
    Yang, J.
    Frias, J. P.
    Browne, S. K.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S33 - S34
  • [47] Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus
    Maryam Eghbali
    Fariba Alaei-Shahmiri
    Nahid Hashemi-Madani
    Zahra Emami
    Ladan Mostafavi
    Mojtaba Malek
    Mohammad E. Khamseh
    Advances in Therapy, 2024, 41 : 826 - 836
  • [48] Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, provides robust HbA1c and body weight reductions to people with type 2 diabetes: a 36-week, phase 2 study
    Coskun, T.
    Rosenstock, J.
    Frias, J.
    Jastreboff, A.
    Du, Y.
    Lou, J.
    Gurbuz, S.
    Hartman, M. L.
    Haupt, A.
    Milicevic, Z.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S31 - S31
  • [49] Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes
    Seino, Y.
    Rasmussen, M. F.
    Nishida, T.
    Kaku, K.
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (05) : 1013 - 1022
  • [50] Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus
    Eghbali, Maryam
    Alaei-Shahmiri, Fariba
    Hashemi-Madani, Nahid
    Emami, Zahra
    Mostafavi, Ladan
    Malek, Mojtaba
    Khamseh, Mohammad E.
    ADVANCES IN THERAPY, 2024, 41 (02) : 826 - 836
12345